Alzheimer's Dementia

Excessive Daytime Sleepiness Linked to β-Amyloid Accumulation in Elderly

March 13, 2018

The researchers found that baseline EDS, defined as an Epworth Sleepiness Scale score of at least 10, was significantly correlated with increased regional Aβ accumulation in the anterior cingulate, posterior cingulate-precuneus, and parietal regions.

Pimavanserin Evaluated in Patients With Alzheimer's Disease Psychosis

February 15, 2018

By week 12, for the overall population there was no significant advantage for pimavanserin versus placebo (treatment difference, −0.51; 95% CI, −2.23 to 1.21; P=0.561). Common adverse events in both groups included falls, urinary tract infections, and agitation.

Study Evaluating Verubecestat in Prodromal Alzheimer's Disease Stopped

By February 14, 2018

APECS is a randomized, placebo-controlled, parallel-group, double-blind Phase 3 clinical trial evaluating the efficacy and safety of verubecestat in people with prodromal AD.

BACE1 Inhibition May Hold Key to Preventing Alzheimer's

February 14, 2018

"Our results demonstrate that sustained and increasing BACE1 inhibition in adults can reverse amyloid deposition in an AD mouse model, and this observation will help to provide guidance for the proper use of BACE1 inhibitors in human patients," the authors write.

Circadian Dysfunction May Serve as Early Alzheimer's Biomarker

January 31, 2018

"The presence of circadian rhythm abnormalities in the preclinical phase of AD suggests that circadian dysfunction could contribute to early disease pathogenesis or serve as a biomarker of preclinical disease," the authors write.

Premature Unusual Amnesia Syndrome Linked to Substance Use

January 30, 2018

"To our knowledge this report is the first to associate fentanyl with this amnestic syndrome," the authors write.

Zonisamide Efficacy Assessed in Dementia With Lewy Bodies

January 25, 2018

The researchers found that the zonisamide 50mg group had significantly greater improvement in Unified Parkinson's Disease Rating Scale part 3 total score at week 12 versus placebo.

Significant Memory, Attention Benefits Associated With Curcumin Supplement

By January 23, 2018

Significant changes in mean FDDNP were found at 18 months in the amygdala and hypothalamus regions of the brain, which control several memory and emotional functions.

Disappointing Results From Latest Trial of Prospective Alzheimer Tx

January 10, 2018

The researchers found that the mean change in the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale was 0.37, 0.61, and 0.41 for the 60- and 30-mg idalopirdine groups and the placebo group, respectively.

Consumption of Green Leafy Vegetables May Slow Cognitive Decline

December 21, 2017

Consumption of median 1.3 servings/day over 4.7 years tied to slower cognitive decline

Interventions Reviewed for Late-Life Dementia Prevention

December 19, 2017

Researchers from the University of Minnesota in Minneapolis reviewed data from 32 trials to examine the effectiveness of physical activity interventions in slowing cognitive decline and delaying the onset of cognitive impairment and dementia.

Model Projects Alzheimer's Disease to Double in U.S. by 2060

December 08, 2017

A differential impact is anticipated for primary and secondary preventions on future disease burden.

New Study Sheds Light on Safety of Gadolinium-Based Contrast Agents

By November 29, 2017

After adjusting for gender, age, education level, baseline neurocognitive performance, and others, the authors reported gadolinium exposure was not a significant predictor of cognitive decline, dementia, diminished neuropsychological performance or diminished motor performance

Anticholinergic Scoring Systems Appraised in Clinical Settings

November 28, 2017

The researchers found that the ACB showed the strongest and most consistent dose-response relationships with risks of all four adverse outcomes compared with ARS and DBI-Ach, especially among those aged 65 to 84 years.

New Immunoassays Show Improvement in Measuring Aβ42 in CSF

November 09, 2017

The researchers found that the mass spectrometry-derived Aβ42 values showed higher correlations with the modified Aβ42-INNOTEST, Aβ42-FL, Aβ42-EI, and Aβ42-MSD assays versus the classic Aβ42-INNOTEST assay.

FDA Grants Alzheimer's Disease Drug Candidate Fast Track Status

By October 25, 2017

The company said in a press release that their pivotal Phase 3 program for ALZ-801 will focus on approval in the genetically-defined subpopulation of high risk patients who are at the Mild stage of AD.

First-in-Class Alzheimer's Drug Gets Fast-Tracked by FDA

By October 16, 2017

CT1812 is a first-in-class, orally-administered small molecule that targets the sigma-2 receptor complex on neuronal synapses, displacing beta amyloid oligomers from their binding sites on brain cells and clearing them in to the cerebrospinal fluid.

No Significant Improvement with Intepirdine in Alzheimer's Disease Study

By September 26, 2017

The study included patients with mild to moderate Alzheimer's disease on donepezil therapy (n= 1315) and compared once-daily oral doses of intepirdine 35mg to placebo over 24 weeks.

High Systolic BP Linked to Negative Cognitive Outcomes

August 23, 2017

Researchers find that healthy reductions may benefit blacks even more than whites

Memantine Started Quickly After TBI May Reduce Levels of Brain Damage Biomarker

By August 04, 2017

Before study initiation, NSE levels were similar for both groups. On Day 3 of the study, the NSE levels were 7.95 ± 2.86 ng/mL for the memantine group and 12.33 ± 7.09 ng/mL for the control group (P=0.05).

Dementia Risk Up in Older Patients with Hearing Loss

July 31, 2017

The researchers found that in cross-sectional analyses, participants with self-reported or objective moderate and poor hearing were more likely to have a dementia diagnosis than those with normal hearing, after adjustment for potential confounders.

Is Fasting Plasma Glucose a Predictor of Alzheimer's in T2D?

July 25, 2017

Both FPG CV and HbA1c CV were significant predictors of AD after adjustment for sociodemographic factors, lifestyle behaviors, diabetes-related variables, FPG and HbA1c, drug-related variables, and comorbidities.

Targeting These 9 Factors May Help Prevent Dementia, Say Experts

July 21, 2017

Addressing these risk factors could help prevent 35 percent of dementia cases, researchers suggest

Study Aims to "Set the Record Straight" on PPIs and Dementia

By July 20, 2017

After multivariable adjustment - which included duration of chronic medical conditions - a modest statistically significant association was only seen for psychomotor speed and attention.

The Puzzles That May Improve Brain Performance

July 18, 2017

"We found direct relationships between the frequency of word puzzle use and the speed and accuracy of performance on nine cognitive tasks assessing a range of aspects of function including attention, reasoning, and memory," researcher Keith Wesnes, PhD.

Certain Diets Linked to Improved Cognitive Function in Older Adults

July 10, 2017

The researchers found that in fully adjusted models, participants with mid and high MedDiet scores were less likely to have poor cognitive performance than those with low scores.

More Sleep May Help Stave off Alzheimer's in Those At Risk

July 07, 2017

The researchers found an association between greater AD pathology and worse subjective sleep quality, more sleep problems, and daytime somnolence.

Is Chocolate the New 'Brain Food'?

By June 29, 2017

"Collectively, these findings seem to support quite consolidated epidemiological evidence indicating that regular cocoa flavanols intake possesses the potential to protect human cognition, particularly in aged populations," write the authors.

Study Examines Link Between PPI Use and Alzheimer's Disease

June 29, 2017

"PPIs were not associated with greater risk of dementia or of Alzheimer's disease, in contrast to recent reports. Study limitations include reliance on self-reported PPI use and lack of dispensing data," the authors write.